792 related articles for article (PubMed ID: 18781676)
21. Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats.
Papathanou M; Rose S; McCreary A; Jenner P
Eur J Neurosci; 2011 Jun; 33(12):2247-54. PubMed ID: 21615558
[TBL] [Abstract][Full Text] [Related]
22. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
23. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
[TBL] [Abstract][Full Text] [Related]
24. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
Stacy M; Galbreath A
Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
[TBL] [Abstract][Full Text] [Related]
25. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
Dupre KB; Eskow KL; Negron G; Bishop C
Brain Res; 2007 Jul; 1158():135-43. PubMed ID: 17553470
[TBL] [Abstract][Full Text] [Related]
26. Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.
Jenner P; McCreary AC; Scheller DK
J Neural Transm (Vienna); 2011 Dec; 118(12):1691-702. PubMed ID: 21881838
[TBL] [Abstract][Full Text] [Related]
27. Myths and realities of continuous dopaminergic stimulation.
Pirtošek Z
Psychiatr Danub; 2011 Mar; 23(1):80-3. PubMed ID: 21448103
[TBL] [Abstract][Full Text] [Related]
28. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.
Olanow CW; Obeso JA; Stocchi F
Lancet Neurol; 2006 Aug; 5(8):677-87. PubMed ID: 16857573
[TBL] [Abstract][Full Text] [Related]
29. Preventing levodopa-induced dyskinesias.
Olanow CW; Obeso JA
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S167-76; discussion S176-8. PubMed ID: 10762145
[TBL] [Abstract][Full Text] [Related]
30. Recognition and treatment of response fluctuations in Parkinson's disease: review article.
Verhagen Metman L
Amino Acids; 2002; 23(1-3):141-5. PubMed ID: 12373528
[TBL] [Abstract][Full Text] [Related]
31. Opioids and motor complications in Parkinson's disease.
Samadi P; Bédard PJ; Rouillard C
Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
[TBL] [Abstract][Full Text] [Related]
32. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
[TBL] [Abstract][Full Text] [Related]
33. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment.
Crossman AR
Mov Disord; 1990; 5(2):100-8. PubMed ID: 1970120
[TBL] [Abstract][Full Text] [Related]
34. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Savola JM; Hill M; Engstrom M; Merivuori H; Wurster S; McGuire SG; Fox SH; Crossman AR; Brotchie JM
Mov Disord; 2003 Aug; 18(8):872-83. PubMed ID: 12889076
[TBL] [Abstract][Full Text] [Related]
35. Pathophysiology of motor fluctuations in Parkinson's disease.
Widnell K
Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
[TBL] [Abstract][Full Text] [Related]
36. Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.
Bhidayasiri R; Ling H
J Med Assoc Thai; 2009 Jan; 92(1):142-54. PubMed ID: 19260256
[TBL] [Abstract][Full Text] [Related]
37. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Stocchi F
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S9-S15. PubMed ID: 19131046
[TBL] [Abstract][Full Text] [Related]
38. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
Encarnacion EV; Hauser RA
Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
[TBL] [Abstract][Full Text] [Related]
39. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
[TBL] [Abstract][Full Text] [Related]
40. Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?
Huot P; Fox SH; Newman-Tancredi A; Brotchie JM
J Pharmacol Exp Ther; 2011 Oct; 339(1):2-8. PubMed ID: 21784889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
